A partitioned survival model was developed to evaluate the cost-effectiveness of dabrafenib plus trametinib versus vemurafenib as a first-line treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a Chinese healthcare system perspective. This evidence concerns the gene BRAF and metastatic melanoma.